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Background: Fatty liver is a major metabolic disorder in dairy cows and is believed to result in major economic
losses in dairy farming due to decreased health status, reproductive performance and fertility. Currently, the
definitive means for diagnosing fatty liver is determining the fat content of hepatic tissue by liver biopsy, which is
an invasive and costly procedure, making it poorly suited to dairy farms. Therefore, the key aim of this study was to
investigate the measurement of serum paraoxonase-1 (PON1), an enzyme exclusively synthesized by the liver, as a
sensitive noninvasive biomarker for diagnosis of fatty liver in dairy cows.
Results: A comparative cohort study using serum specimens from Holstein–Friesian dairy cows (46 healthy and 46
fatty liver cases) was conducted. Serum PON1 (paraoxonase, lactonase and arylesterase) activity and other
biochemical and hematological parameters were measured. We found that serum PON1 activity was lower
(P<0.001) in cows suffering from fatty liver. The area under the receiver operating characteristic curve (AUC-ROC) of
PON1 activity for diagnosis of fatty liver was 0.973–0.989 [95% confidence interval (CI) 0.941, 1.000] which was
higher than the AUC-ROC of aspartate aminotransferase (AST), lecithin-cholesterol acyltransferase (LCAT), alkaline
phosphatase (ALP), non-esterified fatty acids (NEFA), beta-hydroxybutyrate (BHBA), total cholesterol, high-density
lipoprotein (HDL) and low-density lipoprotein (LDL). We found that adding serum PON1 measurement to different
batteries of serum diagnostic panels showed a combination of high sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV), positive likelihood ratio (+LR), negative likelihood ratio (−LR), diagnostic odd
ratio (DOR) and overall diagnostic accuracy in diagnosing fatty liver.
Conclusions: The present results indicate that addition of serum PON1 activity measurement to the biochemical
profile could improve the diagnosis of fatty liver in dairy cows, which would have a considerable clinical impact
and lead to greater profitability in the dairy industry.
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Fatty liver is a major metabolic disorder of transition
dairy cows affecting approximately half of the herd im-
mediately after calving [1]. It is commonly associated
with reduced productivity, fertility and immune func-
tions, and may even lead to liver failure and premature
death [2,3]. Almost all high-producing dairy cows are in
negative energy balance in early lactation, as energy re-
quirements exceed feed consumption capacity [4].
Therefore, fatty liver mainly occurs in the first 4 weeks
after calving [5,6], when the hepatic uptake of lipids* Correspondence: horii@cc.miyazaki-u.ac.jp
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reproduction in any medium, provided the orexceeds the oxidation and secretion of lipids by the liver.
As compared with other species, the bovine liver is inef-
ficient at exporting triglyceride (TG) in very low-density
lipoprotein (VLDL) [2]. This state leads to TG accumu-
lation in the liver, resulting in impaired hepatic metabol-
ism [3]. Although, cows with mild and moderate fatty
liver do not necessarily show clinical signs, the condition
has been associated with health and production prob-
lems [7]. Despite the economic importance of this dis-
ease, it is often misidentified or overlooked due to
difficulties in diagnosis [8].
Paraoxonase-1 (PON1; E.C. 3.1.8.1) is a mammalian
enzyme synthesized exclusively in the liver and secreted
into the blood [9]. It has been shown that PON1 is able
to hydrolyze specific oxidized lipids [10], leading to ad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phages and atherosclerotic lesions [11]. Two possible sub-
strates for bovine PON1 are commonly used. The ability of
PON1 to hydrolyze paraoxon was employed as a method
for measuring paraoxonase activity. PON1 also shows
arylesterase activity, with phenyl acetate being one of its
best substrates [12]. Moreover, in humans and several ex-
perimental studies, PON1 has shown good lactonase activ-
ity, hydrolyzing a wide range of lactones [13].
As compared with the substantial information avail-
able on PON1 from human and experimental animals’
studies, little is known about its roles in cows [14,15].
As the liver plays a key role in the synthesis of serum
PON1, it is plausible that there is an association between
serum PON1 activity and liver impairment during fatty
liver development in dairy cows.
Standard biochemical tests for liver dysfunction are in-
sufficiently sensitive for a reliable diagnosis of fatty liver
in dairy cows; thus, histological examination of liver bi-
opsy for determining fat contents has become the defini-
tive means of diagnosing fatty liver [2], but this is an
invasive and costly procedure, making it poorly suited
for dairy farms. Therefore, finding a sensitive and nonin-
vasive measurement for diagnosis of fatty liver is import-
ant for greater profitability in the dairy industry. The
purpose of this study was to evaluate the diagnostic
power of serum PON1 activity, alone and in combin-
ation with standard liver function tests, in the diagnosis
of fatty liver in dairy cows.
Methods
Animals and serum sampling
The study population included 46 non-pregnant clinically
healthy Holstein-Friesian dairy cows (aged 3–4 years) and
46 non-pregnant Holstein-Friesian dairy cows (of the
same age) suffering from fatty liver. All cows were within
4 weeks postpartum. All healthy cows were confirmed by
physical, serum biochemical and hematological examina-
tions. With regard to selection of cows with fatty liver,
three crucial aspects must be considered: exclusion of
cases with any other pathological conditions such as fever,
abomasal displacement, mastitis, metritis, vaginal dis-
charge, and bone fractures; confirmation of fatty liver
cases was performed by postmortem examination by ex-
pert slaughter house inspectors; and none of the fatty liver
cases suffered from recumbency before slaughter. All cows
were kept on the same farm on Kyushu Island, Japan.
Blood samples were collected from each cow before feed-
ing in the morning from the jugular vein into VacutainerW
(Terumo, Tokyo, Japan) tubes with potassium EDTA (for
hematological analysis) and without anticoagulant (for
serum separation). Tubes were placed in an icebox and
carried to the laboratory within less than 1 h of collection.
After clotting for 2 h on ice, samples were centrifuged at1600× g for 15 min. Farm owner gave informed consent
for cows to be included in the study and undergo the test-
ing procedures. The laboratory protocols were performed
in compliance with the Institutional Review Board for
Animal Experiments of the University of Miyazaki.
Hematological parameters measurement
Hematological variables including white blood cells
(WBCs) and red blood cells (RBCs), hemoglobin (Hgb)
concentration, hematocrit (Hct) value, mean corpuscular
volume (MCV), mean corpuscular hemoglobin (MCH),
and mean corpuscular hemoglobin concentration (MCHC)
were determined using an electronic particle hematology
analyzer (Erma PCE-210N; Diamond Diagnostic, Holliston,
MA, USA).
Biochemical parameters assay
The following parameters were assayed: serum aspartate
aminotransferase (AST), gamma glutamyltranspeptidase
(GGT) and alkaline phosphatase (ALP) (Dri-Chem
3500 V; Fuji-Film Co., Tokyo, Japan) [16]; non-esterified
fatty acids (NEFA) (Wako Pure Chemical Ind., Osaka,
Japan); β-hydroxybutyrate (BHBA) (Sanwa Kagaku
Kenkyusho Co., Ltd., Nagoya, Japan); and triglyceride
(TG), total cholesterol (T.CHOL), high-density lipopro-
tein (HDL), free cholesterol (FC) and phospholipids (PL)
(Wako Pure Chemical Ind., Osaka, Japan); total protein
(TP), albumin (ALB), total bilirubin (T. Bil), glucose
(Glu), blood urea nitrogen (BUN), calcium (Ca), phos-
phorus (P), and magnesium (Mg) (Dri-Chem 7000 V;
Fuji-Film Co.) [16]. Low-density lipoprotein (LDL) was
calculated using the Friedewald equation [17], and VLDL
was calculated using the following formula: triglyceride/5
[18]. Cholesteryl ester (CE) was calculated as T.CHOL
minus FC and ester (E) ratio was calculated by dividing
CE value by T.CHOL value. Albumin/globulin (AG) ratio
was calculated by dividing albumin value by the globulin
value.
PON1 activities measurement
Serum PON1 activity was assayed using three synthetic sub-
strates: paraoxon (diethyl-p-nitrophenyl phosphate; Sigma
Chemical Co., St. Louis, MO, USA); and dihydrocoumarin
(Sigma Chemical Co.); phenyl acetate (Nacalai Tesque, Inc,
Kyoto, Japan) [19]. Briefly, PON1 activity against paraoxon
was determined based on the initial rate of substrate hy-
drolysis to p-nitrophenol by monitoring the absorbance at
412 nm for serum samples in 100 mM Tris–HCl buffer
containing 2 mM paraoxon and 2 mM CaCl2 (pH 8.0).
Enzyme activity was calculated from E412 of p-nitrophenol
(18,290 M−1 cm−1) and expressed in terms of U/mL (where
1 U of enzyme hydrolyses 1 nmol of paraoxon/min), while
the enzyme activities toward dihydrocoumarin and phenyl
acetate were determined by measuring the initial rate of
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serum samples in 100 mM Tris–HCl buffer containing
2 mM substrates, and 2 mM CaCl2 in (pH 8.0). Absorbance
was monitored for dihydrocoumarin and phenyl acetate at
270 nm and enzyme activity was calculated from the E270
of dihydrocoumarin (1295 M−1 cm−1) and phenyl acetate
(1310 M−1 cm−1). Enzyme activities were expressed in
U/mL (where 1 U of enzyme activity hydrolyses 1 μmol of
substrate/min). All activities were measured at 25°C.LCAT activity assay
Serum LCAT activity was assayed using the Calbiochem
Fluorometric LCAT assay kit (EMD Bioscience, San
Diego, CA, USA) according to the manufacturer’s in-
structions with some modifications. Briefly, aliquots
(3 μL) of serum in both control and fatty liver cases were
incubated at 37°C with the fluorescently labeled choles-
terol in assay buffer containing 150 mM NaCl, 10 mM
Tris–HCl, 4 mM β-mercaptoethanol and 1 mM EDTA
at pH 7.4. Total assay volume was 45 μL. After 8 h of in-
cubation at 37°C, 30 μL of the reaction mixture was
added to 90 μL of the READ reagent (150 mM NaCl,
10 mM Tris–HCl, and 1 mM EDTA at pH 7.4). Conver-
sion of cholesterol (Em. 470 nm) to cholesteryl ester
(Em. 390 nm) at 340 nm excitation was determined in a
fluorescence microplate reader (VICTOR Multilabel
Plate Reader, PerkinElmer, Inc., Waltham, MA, USA).
The change in ratio of the two intensities (470/390) was
then calculated.Statistical analysis
We used ShapiroWilks test to examine whether variables
were distributed normally. Following data distribution,
differences between study groups were tested by using
independent samples t-test and Mann–Whitney U test.
Correlation coefficients were calculated by Spearman’s
method. Partial correlation coefficients were calculated
among selected blood variables, corrected for animal
groups. Diagnostic accuracy for serum PON1 and other
biochemical tests was calculated with receiver operating
characteristic (ROC) curve analysis [20,21]. Logistic re-
gression was used to estimate the ability of groups of
variables to predict the presence or absence of liver dis-
ease. Sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV), positive likeli-
hood ratio (+LR), and negative likelihood ratio (−LR)
were computed with the corresponding 95% confidence
intervals (CI). We also calculated the diagnostic odds ra-
tio (DOR) which expresses the strength of the associ-
ation between the test result and disease [22]. Statistical
analysis was performed using the statistical software
package SPSS for Windows (version 18.0; SPSS Inc.,
Chicago, IL, USA). Statistical significance between meanvalues was set at P < 0.05. Data are reported as means
and standard deviations (SD).Results
Clinical signs
No clinical signs were observed in the control group at
the time of sample collection. On the other hand, the
diseased cases showed decreased appetite, rough fur,
weak ruminal movement, loss of abdominal circumfer-
ence, decreased milk yield, rapid deterioration of body
conditions and sometimes watery diarrhea.Biochemical and hematological parameters
Table 1 shows the biochemical and hematological pa-
rameters in healthy cows and cases with fatty liver.
Serum PON1 (paraoxonase, lactonase and arylesterase)
activity was significantly reduced (−53%, –56%, and
−36%, respectively; P<0.001), in cases with fatty liver, as
compared to controls.
Other biochemical parameters supported the presence
of fatty liver, as manifested by significant increases in
AST (101%; P<0.001), NEFA (440%; P<0.001), BHBA
(305%; P<0.001), total bilirubin (T. Bil) (245%; P<0.001)
and TG (30%; P<0.01). Fatty liver cases also showed sig-
nificant decreases in LCAT (−16%; P<0.05), T.CHOL
(−66%; P<0.001), HDL (−38%; P<0.001), VLDL (−43%;
P<0.001), LDL (−83%; P<0.001), FC (−60%; P<0.001), CE
(−68%; P<0.001), PL (−70%; P<0.001), E. ratio (−6%;
P<0.05), ALB (−8%; P<0.001) and A/G ratio (−11%;
P<0.01). In addition, significant hypocalcemia (P<0.001)
and hypomagnesmia (P<0.001) were associated with fatty
liver cases. There were non-significant changes in the
concentrations of total protein, glucose, blood urea ni-
trogen and phosphorus.
For hematology parameters, cases with fatty liver
showed a significant (P<0.01) decrease in the number of
RBCs, as well as significant (P<0.001) increases in the
volume of RBCs and hemoglobin content, as indicated
by increased MCV and MCH, leading to a state of mac-
rocytic anemia.
Diagnostic performance was evaluated by ROC ana-
lysis with pertinent areas under the curve (AUCs). AUCs
with the corresponding cut-off and p values are listed in
Figures 1 and 2. Curves for paraoxonase, lactonase,
arylesterase, AST, ALP and LCAT appear in Figure 1.
The AUCs for PON1 (paraoxonase, lactonase and
arylesterase) activity were 0.989, 0.983 and 0.973 respect-
ively, which were higher than those of other liver en-
zymes (AST, LCAT and ALP showed AUCs of 0.881,
0.702 and 0.688, respectively). NEFA, BHBA, total chol-
esterol, HDL, LDL and phospholipids showed AUCs of
0.960, 0.925, 0.960, 0.833, 0.935 and 0.941, respectively
(Figure 2).
Table 1 Serum biochemical and hematological parameters from healthy reference cows and cows with fatty liver
Control (n=46) Fatty liver (n=46) % change Distribution P value ≤
Biochemical parameters
Paraoxonase (U/mL) 82.11 ± 22.42 38.47 ± 13.40 −53.14 0.029 0.001
Lactonase (U/mL) 5.82 ± 1.70 2.56 ± 1.11 −55.86 0.043 0.001
Arylesterase (U/mL) 47.92 ± 7.36 30.44 ± 7.88 −36.48 0.028 0.001
AST (U/L) 67.84 ± 14.53 136.78 ± 68.14 101.62 0.000 0.001
GGT (U/L) 44.18 ± 10.43 49.93 ± 30.25 13.02 0.068 0.903
ALP (U/L) 232.45 ± 73.10 225.69 ± 84.07 −2.907 0.048 0.871
LCAT (470/390) 3.80 ± 1.10 3.20 ± 0.84 −15.81 0.000 0.015
T. Bil (μmol/L) 5.30 ± 2.22 18.31 ± 7.69 245.28 0.000 0.001
NEFA (mmol/L) 0.22 ± 0.20 1.19 ± 0.60 440.90 0.000 0.001
BHBA (mmol/L) 0.725 ± 0.31 2.94 ± 1.77 305.51 0.000 0.001
T.CHOL (mmol/L) 4.71 ± 1.17 1.58 ± 0.61 −66.45 0.171 0.001
HDL (mmol/L) 1.94 ± 0.71 1.19 ± 0.001 −38.65 0.048 0.001
VLDL (mmol/L) 0.141 ± 0.05 0.08 ± 0.05 −43.26 0.808 0.001
LDL (mmol/L) 2.72 ± 1.71 0.44 ± 0.37 −83.82 0.001 0.001
TG (mmol/L) 0.30 ± 0.12 0.39 ± 0.14 30.00 0.808 0.002
FC (mmol/L) 0.94 ± 0.35 0.37 ± 0.15 −60.63 0.135 0.001
CE (mmol/L) 3.84 ± 1.49 1.20 ± 0.53 −68.75 0.177 0.001
E. ratio 80.12 ± 3.73 75.12 ± 9.95 −6.24 0.000 0.014
PL (mmol/L) 2.89 ± 1.05 0.85 ± 0.29 −70.58 0.036 0.001
TP (g/L) 70.92 ± 5.60 69.10 ± 6.8 −2.56 0.005 0.749
ALB (g/L) 35.5 6 ± 2.56 32.59 ± 3.31 −8.565 0.018 0.001
AG ratio 1.032 ± 0.19 0.91 ± 0.18 −11.614 0.570 0.004
GLU (mmol/L) 2.55 ± 0.61 2.74 ± 0.15 7.45 0.004 0.739
BUN (mmol/L) 12.69 ± 8.49 5.40 ± 6.70 −57.44 0.000 0.083
Ca (mmol/L) 2.56 ± 0.15 2.21 ± 0.27 −13.67 0.000 0.001
P (mmol/L) 1.92 ± 0.31 2.05 ± 0.90 6.77 0.462 0.657
Mg (mmol/L) 1.05 ± 0.12 0.90 ± 0.12 −14.28 0.000 0.001
Hematological parameters
WBCs (109/L) 8.045 ± 1.88 8.87 ± 5.48 10.267 0.000 0.188
RBCs (1012/L) 5.94 ± 0.67 5.35 ± 1.18 −9.951 0.937 0.002
Hgb (g/L) 98.52 ± 10.13 98.17 ± 21.60 −0.441 0.637 0.795
HCT% 26.86 ± 4.26 26.90 ± 2.16 0.138 0.015 0.924
MCV (fL) 45.65 ± 4.95 50.21 ± 6.14 9.990 0.239 0.001
MCH (pg) 16.65 ± 1.70 18.33 ± 1.57 10.132 0.948 0.001
MCHC (g/L) 36.66 ± 2.84 35.96 ± 5.66 −1.909 0.284 0.478
PLT (109/L) 398.28 ± 114.99 351.36 ± 99.68 −11.779 0.484 0.001
Data are presented as mean values ± standard deviation of mean.
AST, aspartate aminotransferase; GGT, gamma glutamyltransferase; ALP, alkaline phosphatase; LCAT, lecithin-cholesterol acyltransferase; T. Bil, total bilirubin; NEFA,
non-esterified fatty acids; BHBA, beta-hydroxybutyrate; T.CHOL, total cholesterol; HDL, high-density lipoprotein; VLDL, very low-density lipoprotein; LDL, low-
density lipoprotein; TG, triglyceride; FC, free cholesterol; CE, cholesteryl ester; E. ratio, ester ratio; PL, phospholipids; TP, total protein; ALB, albumin; AG, albumin/
globulin ratio; GLU, Glucose; BUN, blood urea nitrogen; Ca, total serum calcium; P, inorganic phosphorus; Mg, magnesium; WBC, total white blood cell count; RBC,
total red blood cell count; Hg, hemoglobin content; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean
corpuscular hemoglobin concentration; and PLT, platelet count.
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Figure 1 Receiver operating characteristic (ROC) curves for diagnostic efficacies of PON1 and some other liver enzymes. ROC curves
were evaluated for serum PON1 (paraoxonase, arylesterase and lactonase), AST, ALP and LCAT activities in the prediction of fatty liver in dairy
cow. AUC, Area under ROC curve; SEM, standard error of mean.
Figure 2 Receiver operating characteristic (ROC) curves for diagnostic efficacies of serum lipid metabolism indicators. ROC curves were
evaluated for serum NEFA, BHBA, total cholesterol, HDL, LDL and phospholipids in the prediction of fatty liver in dairy cow. AUC, Area under ROC
curve; SEM, standard error of mean.
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cients of the regression lines between serum PON1 ac-
tivity and the other biochemical analytes, Spearman and
partial correlation coefficients are depicted in Table 2
below and above the diagonal, respectively. Spearman
correlation (below the diagonal) showed significant cor-
relations between paraoxonase activity and indicators of
liver damage or dysfunction [AST (r=−0.50; P<0.01),
total bilirubin (r=−0.65; P<0.01) and LCAT (r=0.27;
P<0.05)], with indicators of fat mobilization [NEFA (r=
−.66; P<0.01), and BHBA (r=−0.56; P<0.01)], as well as
significant correlations with indicators of hepatic synthe-
sis and metabolic abilities [albumin (r=0.49; P<0.01),
total cholesterol (r=0.82; P<0.01), HDL (r=0.62; P<0.01),
VLDL (r=0.32; P<0.01), LDL (r=0.72; P<0.01), triglycer-
ides (r=0.24; P<0.05), free cholesterol (r=0.79; P<0.01),
and cholesterol ester (r=0.81; P<0.01)] support the no-
tion that PON1 activity is a good reflection of hepatic
function. Notably, the three activities of PON1
(paraoxonase, lactonase and arylesterase) in dairy cow
showed significant positive correlations (r=0.96–97;
P<0.01) with one another. On the other hand, when the
animal health conditions were controlled, partial correl-
ation coefficients (above the diagonal), showed that there
are no correlations between paraoxonase and the indica-
tors of liver damage and fat mobilization (AST, LCAT,
total bilirubin, NEFA and BHBA). We can infer that the
relationship between PON1 activity and liver damage or
dysfunction biomarkers is mediated by fatty liver.
The usefulness of adding serum PON1 measurement
to the biochemical panel of liver function tests was ana-
lyzed by multiple logistic regression analysis. This
showed that adding PON1 values to other biochemical
results increases the sensitivity, specificity, PPV, NPV
and likelihood ratios (positive and negative), as well as
overall diagnostic accuracy. The optimum diagnostic cut
off point maximizing the sensitivity and specificity was
determined to be 53.21 U/mL for paraoxonase activity,
with a sensitivity of 86.7% and specificity of 93.5%. The
corresponding PPV and NPV levels were 93.48% and
86.67%, respectively. Adding PON measurement to other
biochemical parameters improves the diagnostic indices
by increasing +LR, decreasing -LDR, and greatly increas-
ing DOR. As shown in Table 3, the best performance
was observed with a combination of paraoxonase and
NEFA measurements, and paraoxonase, NEFA, BHBA,
AST, LCAT and total cholesterol.Discussion
The liver plays a pivotal role during the transition period
of dairy cows, and its functions are necessary for suc-
cessful adaptation without the occurrence of health dis-
orders [23]. Therefore, finding suitable noninvasive testsfor improving the evaluation of liver function and aiding
in diagnosis of fatty liver is urgently necessary.
There are no standardized methods for measuring PON1
esterase activity. The most widely used method is the hy-
drolysis of paraoxon. However, this method is not free of
drawbacks. Firstly, paraoxon is very unstable and extremely
toxic, which is not suitable for a high-throughput routine
method. Secondly, the interpretation of the physiological
significance of a measurement conducted with such an un-
natural substrates is questionable. In addition, the enzyme’s
activity on paraoxon is strongly influenced by the PON1192
genetic polymorphism (which is not well studied in bovine)
[24]. Recent significant advances in the search for reliable
PON1 lactonase activity assays may facilitate the measure-
ment in a routine clinical chemistry laboratory setting [25].
This study is the first to measure lactonase activity in bo-
vine samples, which makes PON1 measurement closer to
practical development in veterinary field. In the present
study, we found that serum PON1 (paraoxonases,
lactonase and arylesterase) activity is significantly reduced
in cows with fatty liver, as compared with controls. Several
mechanisms may explain this decrease in serum PON1 ac-
tivity. First, PON1 activity may be decreased as a result of
altered PON1 synthesis by the liver [26,27], possibly due to
increased hepatic and serum proinflammatory cytokine
(TNF-α) in cows with fatty liver [2,28]. Second, reductions
in serum PON1 activity in fatty liver cases might be attrib-
uted to changes in HDL structure and composition [29],
and this is supported by our findings of decreased LCAT
activity in fatty liver cases, which is in accordance with the
results of Nakagawa et al., (1997) [30]. Both PON1 and
LCAT are HDL-associated proteins. Accordingly, the re-
duction in serum PON1 and LCAT activities appears to be
mediated by alterations in HDL structure and concentra-
tion, which may be primarily caused by fatty liver [31].
Finally, cows with fatty liver showed increased free radical
production manifested by high levels of malondialdehyde
[32], and PON1 is known to be inactivated after hydrolysis
of lipid peroxides [33].
In normal dairy cows, lipid accumulates in the liver
chiefly in the form of triglycerides, this accumulation
reaches up to 10 times the normal value in cows suffering
from fatty liver [8,34]. It is conceivable that this accumula-
tion of triglycerides in the cytoplasm of hepatocytes causes
disturbances in hepatic structure and function [34].
Enzyme leakage from hepatocytes is one manifestation of
these disturbances. Serum AST increases significantly in
accordance with serious hepatic damage induced by fatty
accumulation [28]. This is supported by significant positive
correlations between AST and NEFA (r=0.64; P<0.01) and
BHBA (r=0.67; P<0.01). Although AST activity is relatively
high and in similar amounts in liver and in skeletal and
cardiac muscle, suggesting that it is not liver specific [35],
but its diagnostic sensitivity is reported to be 94% for fatty
Table 2 Spearman and partial correlation coefficients for selected blood variables from healthy cows and cows with fatty liver below and above the diagonal,
respectively
Par Lact Aryl AST ALP LCAT TBil NEFA BHBA T.CHOL HDL VLDL LDL TG FC CE PL TP ALB BUN Ca Mg
Para 1 .96** .83** .49** .37** .36** .45** .48** .40** .23*
Lact .97** 1 .85** .22* .49** .32** .38** .42** .48** .38** .27*
Aryl .97** .96** 1 .23* .29* .31* .44** .43** .28* .38** .44** .32** .33**
AST -.50** -.48** -.47** 1 .25*
ALP .33** .31** .34** 1 .32**
LCAT .27* .28** .28** 1 .51** .61** .41** .51** .43**
TBil -.65** -.64** -.63** .56** -.31** 1 .63** .50**
NEFA -.66** -.65** -.65** .64** -.35** -.23* .83** 1 .52**
BHBA -.56** -.55** -.55** .67** .76** .72** 1 .37**
T.CHOL .82** .81** .81** -.55** .34** .37** -.70** -.70** -.58** 1 .39** .90** .87** .99** .80** .46**
HDL .62** .60** .63** -.38** .52** -.50** -.54** -.45** .74** 1 .31** .40** .35** .41** .31** .27*
VLDL .32** .30* .30** -.37** -.36** -.25* -.33** .44** 1
LDL .72** .73** .70** -.50** .50** -.57** -.62** -.44** .89** .43** .44** 1 .80** .89** .71** .30*
TG .24* .22* .25* -.26* -.29** .33** 1** .44** 1 .81** .72** .29*
FC .79** .76** .76** -.54** .32** .35** -.64** -.66** -.53** .88** .63** .42** .84** .29** 1
CE .81** .80** .81** -.55** .35** .35** -.69** -.70** -.58** .99** .74** .43** .89** .32** .83** 1 .79** .48**
PL .77** .76** .76** -.48** .28* .38** -.69** -.67** -.55** .91** .64** .37** .83** .25* .84** .89** 1 .36** -.33**
TP 1 .24*
ALB .49** .50** .52** -.30** -.27* .55** .56** .30** .55** .24* .49** .56** .50** .38** 1 .24* .39**
BUN .23* .31** .26* .22* .37** 1
Ca .67** .65** .66** -.47** .43** -.62** -.53** -.53** .68** .67** .39** .60** .29** .63** .69** .64** .59** 1
Mg .46** .46** .46** -.43** .35** -.59** -.55** -.56** .58** .47** .31** .41** .21* .48** .59** .51** .41** .25* .55** 1


















Table 3 Performance characteristics of best variables for diagnosis of fatty liver
Test/panel of tests Sensitivity Specificity PPV NPV +LR –LR DOR Accuracy
% 95% CI % 95% CI % 95% CI % 95% CI 95% CI 95% CI 95% CI %
PON 86.7 75.7–94.2 93.5 80.9 –97.5 92.8 81.0–98.3 87.7 72.5–94.4 12.2 4.1–36.7 0.1 0.0–0.2 93.1 21.8 –398.0 90.1
NEFA 92.8 81.3 –97.6 86.9 72.5–98.1 86.6 73.0–94.5 92.0 79.4–98.1 6.9 3.2–14.7 0.0 0.0–0.2 86.6 20.2–371.0 89.7
NEFA+PON 99.7 89.6–99.8 95.2 83.0–99.1 95.4 83.7–99.1 99.7 89.2–99.8 21.0 5.6–78.6 0.0 0.0 –1.1 8440.0 14.6–4871511.6 97.7
NEFA+BHBA 92.8 81.3–97.6 90.9 77.4–96.1 90.6 77.4–97.0 93.0 79.4–98.1 9.5 3.7–24.2 0.0 0.0 – 0.2 123.3 25.8–588.2 91.8
NEFA+BHBA+PON 97.6 87.9–99.5 95.4 83.8–98.6 95.3 83.3–99.2 97.6 85.9–99.8 20.0 5.1–77.4 0.0 0.0–0.1 819.0 71.4–9393.6 96.5
NEFA+BHBA+AST 92.5 79.0–98.1 90.2 75.9–96.8 90.2 77.4–97.0 93.0 78.5–98.0 9.7 3.8–24.7 0.0 0.0–0.2 166.5 28.6–966.1 91.6
NEFA+BHBA+AST+PON 97.5 86.8–99.5 95.4 83.5–98.6 95.1 83.3–99.2 97.6 85.2–99.8 19.4 5.0–75.3 0.0 0.0–0.1 722.0 62.7–8301.8 96.4
NEFA+BHBA+AST+LCAT 94.8 82.7–98.5 90.0 77.4–96.1 90.2 75.4–96.7 94.7 81.3–99.1 9.7 3.8–24.7 0.0 0.0–0.2 166.5 28.6–966.1 92.4
NEFA+BHBA+AST+LCAT+PON 97.4 86.8-99.5 95.0 83.5–98.6 95.0 81.7–99.1 97.4 84.9–99.8 19.4 5.0–75.3 0.0 0.0–0.1 722.0 62.7–8301.8 96.2
NEFA+BHBA+AST+LCAT+T.CHOL 97.4 86.8–99.5 95.0 83.5–98.6 95.0 81.7–99.1 97.4 84.9–99.8 19.4 5.0–75.3 0.0 0.0–0.1 722.0 62.7–8301.8 96.2
NEFA+BHBA+AST+LCAT+T.CHOL+PON 99.7 88.4–99.8 97.2 84.9–99.8 97.2 84.9–99.8 99.7 88.4–99.8 36.4 –5.7–230.2 0.0 0.0–1.2 13898.2 21.1–9140510.2 98.7
NPV, negative predictive value; PPV, positive predictive value; +LR, positive likelihood ratio; –LR, negative likelihood ratio; DOR, diagnostic odd ratio.
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http://www.biomedcentral.com/1746-6148/9/73liver in dairy cows with a strong correlation between serum
activity and liver triglyceride content [36]. On the other
hand, GGT is almost entirely associated with the biliary
epithelium in the liver and is consequently not released
into circulation until bile damage occurs. It seems likely
that fat infiltration, during fatty liver development in our
study, does not induce either cholestasis or bile duct dam-
age, as no significant correlations were observed between
GGT and other biochemical parameters. This is supported
by non-significant changes in serum ALP concentration
instead of the expected increases. Taken together, the re-
sults for GGT and ALP values indicate that fat infiltration
in the liver does not induce intraluminal pressure leading
to intrahepatic obstruction of the bile ducts. We also
found significant hyperbilirubinemia in the fatty liver
group, which suggests liver damage caused by increased
unconjugated bilirubin [37]. The higher bilirubin levels
observed in fatty liver group could be also explained with
a lower liver synthesis of the enzymes necessary to remove
bilirubin from the blood; these enzymes could be also con-
sidered as negative acute phase proteins [38].
We found a significant increase in the concentration of
serum NEFA levels. Elevated NEFA concentrations are a
common factor in the induction of fatty liver, reflecting
excessive mobilization of body fat to cope with the high
energy demand of milk synthesis. Under such conditions,
which are associated with marked formation of acetyl co-
enzyme A, the tricarboxylic acid cycle cannot fully
metabolize fatty acids. As a result, acetyl coenzyme A is
converted to acetoacetate, which is then reduced to BHBA
by BHB dehydrogenase or spontaneously decarboxylized
to acetone [39]. This explains our observation of a signifi-
cant increase in the concentration of BHBA in fatty liver
cases. This increase in BHBA concentration is known to
precede and be associated with the development of fatty
liver [40].
As the liver occupies a central position in bovine me-
tabolism, fatty liver is accompanied by disturbances in
hepatic structure and function [34]; therefore, cows with
fatty liver may also show abnormal lipid and lipoprotein
concentrations [41]. In our study, cows with fatty liver
showed a significant decrease in total cholesterol, which
was inversely related to NEFA concentrations. These re-
sults are in accordance with previous reports [8]. The
decrease in serum HDL may have resulted from im-
paired hepatic secretion of apolipoprotein A, the basic
protein for the synthesis of HDL, that is considered a
negative acute phase protein, and thus the reduction in
HDL could be caused by an inflammatory condition
[3,42] and may be related to the lower cholesterol levels
seen in cows with fatty liver, as HDL consists of about
60% cholesterol [43].
We also found a significant decrease in VLDL in the
fatty liver group, as compared with healthy cows. Severalprevious studies have noted that the accumulation of fat
in the liver cells and development of fatty liver is caused
by reduced synthesis of VLDL [44,45]. Decreased VLDL
secretion and decreased conversion to LDL explains our
findings of decreased serum LDL levels in cows with fatty
liver. Another possible reason for the decreased LDL
levels is the increased rate of LDL catabolism [46]. The de-
creased concentrations of phospholipids (fatty acyl donor
in LCAT reaction) and free cholesterol (fatty acyl acceptor)
observed in cows with fatty liver may be a consequence of
reduced LCAT activity [3]. The decrease in CE concentra-
tion also appeared to be attributable, at least in part, to the
decreased LCAT activity and other enzymes responsible
for cholesterol synthesis, such as hydroxymethylglutaryl
(HMGT)-CoA reductase [47]. An unexpected clinicopath-
ological observation in our study was the significant in-
crease, instead of the expected decrease, in plasma
triglyceride concentrations in cows with fatty liver when
compared with the control group. Although this observa-
tion is supported by the work of Basoglu et al., (2002) [48],
it requires further investigation.
We found a significant hypoalbuminemia in fatty liver
cases as a result of decreased volume of rough endoplasmic
reticulum and mitochondrial damage [40] induced by fat
infiltration of hepatic tissue. In addition, albumin is a nega-
tive acute phase protein and extensive inflammation may
compound this hypoalbuminemia [37]. Moreover, low A/G
ratio in the presence of normal total protein indicates ele-
vated globulins in response to acute inflammation [37].
Serum glucose concentration was not significantly dif-
ferent between healthy and fatty liver cases. This finding
may be due to insulin resistance, which commonly ac-
companies fatty liver in dairy cows [2]. This finding is
in accordance with the results of Kalaitzakis et al.
(2006) [36].
Despite the importance of histopathological examin-
ation of hepatic tissue, Japanese regulations prevented
us from doing this in the present study. However, in
our study we have confirmed the presence of fatty liver
by postmortem examination which considered, regard-
less the degree of fatty liver, as a strong evidence for its
presence in diseased animals. Postmortem examination
of cows with fatty liver revealed swelling of the hepatic
parenchyma, which increased the size and the volume
of the organ [49]. Additionally, from the practical point
of view, lipid profile disturbances and LCAT activity are
useful serum biomarkers for diagnosis of fatty liver in
cows [3] that enable us to confirm the diagnosis of fatty
liver cases in our study. However, the lack of postmor-
tem examinations on the control cows is a limitation of
the study. Acknowledging such limitation of our study,
future investigations are required to assess the correl-
ation between serum PON1 activity and hepatic triglyc-
erides in both healthy and diseased cows.
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http://www.biomedcentral.com/1746-6148/9/73Severe fatty liver does not always result in measurable
hepatic dysfunction. Due to the apparent variability in
the usefulness of biopsy in determining the severity and/
or diagnosis of clinical disease [6], a “battery” of tests
needs to be performed to increase the sensitivity and
specificity of diagnosis. Among the direct biomarkers of
fatty liver, we found good diagnostic performance for
NEFA, BHBA, AST and lipid profile. These biomarkers
showed excellent predictive value for diagnosis of fatty
liver. Notably, addition of serum PON1 to these bio-
chemical tests gave a combination of high sensitivity,
specificity, PPV, NPV, +LR, –LR, DOR and overall diag-
nostic accuracy in diagnosing fatty liver (Table 3). The
AUC-ROC of PON1 activity for the detection of fatty
liver was more than 98% accurate, which has not been
achieved through other diagnostic algorithms.
Importantly, from an economic point of view, the com-
bined measurement of PON1 activity and NEFA concentra-
tion would be useful for diagnosing cows with fatty liver as it
provides sensitivity, specificity, PPV, NPV, +LR, -LR, DOR
and overall diagnostic accuracy comparable to that produced
by the combination of NEFA, BHBA, AST, LCAT, total chol-
esterol, and PON1. Moreover, the strong correlations
between serum PON1 and AST, LCAT, total bilirubin,
NEFA, BHBA and lipid profile make serum PON1 measure-
ment advantageous in diagnosis of fatty liver (Table 3).
It is noteworthy that the measurement of serum
PON1 activity is a simple, reliable, fast, inexpensive,
readily automated method that is compatible with ran-
dom access analysis in barcoded primary tubes, and can
be performed with most automated analyzers used in
standard biochemical liver function tests [50]. The only
drawback, the use of the toxic substrate paraoxon, can
be overcome using the nontoxic lactonase activity, as
our results (Table 2) showed a good correlation between
paraoxonase and lactonase activity in bovine serum.
Conclusions
In conclusion, this study demonstrates that addition of
serum PON1 activity measurement to the biochemical
profile could improve the diagnosis of fatty liver in dairy
cows. Future studies in this area should focus on the
correlation between serum PON1 activity and hepatic
triglycerides content in both healthy and ill dairy cows
as well as the diagnostic validation of serum PON1 assay
in the early prediction of fatty liver development in dairy
farms, which would have a considerable clinical impact
and lead to greater profitability in the dairy industry.
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